<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485796</url>
  </required_header>
  <id_info>
    <org_study_id>161101</org_study_id>
    <nct_id>NCT01485796</nct_id>
  </id_info>
  <brief_title>Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD</brief_title>
  <official_title>Tolerability, Safety and Administration Mode Evaluation of Recombinant Human Hyaluronidase (rHuPH20) Facilitated Subcutaneous Treatment With Immune Globulin Infusion (Human), 10% in Subjects With Primary Immunodeficiency Diseases (PIDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to acquire additional data on safety and tolerability of
      recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune
      Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration.

      Following a discussion with the FDA at the end of July 2012, all participants still active in
      the study stopped treatment with rHuPH20 to assure safety of the participants participating
      in the study and went into a safety follow-up.

      During this safety follow-up period, participants underwent treatment with the licensed
      product IGI, 10% (Gammagard Liquid). The intravenous or subcutaneous administration route was
      at the discretion of the participant and the investigator.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 29, 2011</start_date>
  <completion_date type="Actual">January 1, 2013</completion_date>
  <primary_completion_date type="Actual">January 1, 2013</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Related Systemic Adverse Events (Excluding Infections)</measure>
    <time_frame>7 months (per subject)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2</measure>
    <time_frame>6 months (per subject)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks</measure>
    <time_frame>6 months (per subject)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Related Local Adverse Events (Excluding Infections)</measure>
    <time_frame>7 months (per subject)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Related Local Adverse Events (Excluding Infections) Per Infusion</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Related Adverse Events (Excluding Infections)</measure>
    <time_frame>7 months (per subject)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of All Adverse Events (Excluding Infections) Per Infusion</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20</measure>
    <time_frame>7 months (per subject)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Levels of Immunoglobulin G (IgG)</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusions Per Month in Epoch 1 and Epoch 2</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>Non-parametric descriptive statistics (median, range) are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>Non-parametric descriptive statistics (median, range) are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Infusion in Epoch 1 and Epoch 2</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>Non-parametric descriptive statistics (median, range) are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Infusion Rate in Epoch 1 and Epoch 2</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>Non-parametric descriptive statistics (median, range) are provided.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Weeks to Reach Final 3 or 4-week Dose Interval</measure>
    <time_frame>7 months (per subject)</time_frame>
    <description>Non-parametric descriptive statistics (median, range) are provided.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Primary Immunodeficiency Diseases (PID)</condition>
  <arm_group>
    <arm_group_label>Epoch 1 and Epoch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subjectÂ´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Immune Globulin Infusion (Human), 10%</intervention_name>
    <description>Subcutaneous administration will be used in Study Epochs 1 and 2.</description>
    <arm_group_label>Epoch 1 and Epoch 2</arm_group_label>
    <other_name>IGI</other_name>
    <other_name>10%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant human hyaluronidase</intervention_name>
    <description>rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.</description>
    <arm_group_label>Epoch 1 and Epoch 2</arm_group_label>
    <other_name>rHuPH20</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a documented diagnosis of a form of primary humoral immunodeficiency
             involving a defect in antibody formation and requiring gammaglobulin replacement, as
             defined according to the IUIS Scientific Committee 2009 and by diagnostic criteria
             according to Conley et al. The diagnosis must be reviewed by the Medical Director
             prior to enrollment.

          -  Subject is 2 years or older at the time of screening.

          -  Written informed consent is obtained from either the subject or the subject's legally
             authorized representative prior to any study-related procedures and study product
             administration.

          -  Subject has been receiving a consistent dose of immunoglobulin G (IgG) with a
             non-Baxter product (Gammunex administered IV, Hizentra, or Privigen), administered in
             compliance with the respective product information, for a period of at least 3 months
             prior to screening. The average minimum pre-study dose over that interval was
             equivalent to 300 mg/kg BW/4 weeks and a maximum dose equivalent to 600 mg/kg BW/4
             weeks at a dosing frequency as follows:

               -  For IV treatment prior to the study: at mean intervals of 3 or 4 weeks (+/- 3
                  days) or

               -  For SC treatment prior to the study: at mean intervals of approximately 1 or 2
                  weeks (+/- 2 days).

          -  Subject has a serum trough level of IgG &gt; 5 g/L at screening.

          -  Subject has not had a serious bacterial infection within the 3 months prior to
             screening.

          -  If female of childbearing potential, subject presents with a negative pregnancy test
             and agrees to employ adequate birth control measures for the duration of the study.

          -  Subject is willing and able to comply with the requirements of the protocol.

        Exclusion Criteria:

          -  Subject has a known history of or is positive at screening for one or more of the
             following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for
             hepatitis C virus (HCV), PCR for human immunodeficiency virus (HIV) Type 1/2.

          -  Abnormal laboratory values at screening meeting any one of the following criteria
             (abnormal tests may be repeated once to determine if they are persistent):

               -  Persistent alanine aminotransferase (ALT) and aspartate amino transferase (AST) &gt;
                  2.5 times the upper limit of normal for the testing laboratory

               -  Persistent severe neutropenia (defined as an absolute neutrophil count [ANC] &lt;=
                  500/mm3).

          -  Subject has creatinine clearance (CLcr) value that is &lt;60% of normal for age and
             gender either measured, or calculated according to a gender-specific formula provided
             in the study protocol.

          -  Subject has been diagnosed with or has a malignancy (other than adequately treated
             basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix),
             unless the disease-free period prior to screening exceeds 5 years

          -  Subject is receiving anti-coagulation therapy or has a history of thrombotic episodes
             (including deep vein thrombosis, myocardial infarction, cerebrovascular accident,
             pulmonary embolism) within 12 months prior to screening or a history of thrombophilia.

          -  Subject has abnormal protein loss (protein losing enteropathy, nephrotic syndrome).

          -  Subject has anemia that would preclude phlebotomy for laboratory studies, according to
             standard practice at the site.

          -  Subject has an ongoing history of hypersensitivity or persistent reactions (urticaria,
             breathing difficulty, severe hypotension, or anaphylaxis) following IV immunoglobulin,
             SC immunoglobulin, and/or Immune Serum Globulin (ISG) infusions.

          -  Subject has immunoglobulin A (IgA) deficiency (IgA less than 0.07g/L) and known anti
             IgA antibodies.

          -  Subject has a known allergy to hyaluronidase.

          -  Subject is on preventative (prophylactic) systemic antibacterial antibiotics at doses
             sufficient to treat or prevent bacterial infections, and cannot stop these antibiotics
             at the time of screening.

          -  Subject has active infection and is receiving antibiotic therapy for the treatment of
             infection at the time of screening.

          -  Subject has a bleeding disorder or a platelet count less than 20,000/Î¼L, or who, in
             the opinion of the investigator, would be at significant risk of increased bleeding or
             bruising as a result of SC therapy.

          -  Subject has total protein &gt; 9 g/dL or myeloma, or macroglobulinemia (IgM) or
             paraproteinemia.

          -  Women of childbearing potential meeting any one of the following criteria:

               -  Subject presents with a positive pregnancy test

               -  Subject is breast feeding

               -  Subject intends to begin nursing during the course of the study

               -  Subject does not agree to employ adequate birth-control measures (e.g.
                  intrauterine device, diaphragm or condom [for male partner] with spermicidal
                  jelly or foam, or birth control pills/patches) throughout the course of the
                  study.

          -  Subject has participated in another clinical study and has been exposed to an
             investigational product (IP) or device within 30 days prior to study enrollment
             (exception: treatment with immunoglobulin pre-study).

          -  Subject is scheduled to participate in another (non-Baxter) clinical study involving
             an IP or device during the course of the study.

          -  Subject has severe dermatitis that would preclude adequate sites for safe product
             administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leman Yel, MD</last_name>
    <role>Study Director</role>
    <affiliation>Baxalta US Inc., now part of Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMMUNOe International Research Centers</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates of the Palm Beaches, PA</name>
      <address>
        <city>North Palm Beach</city>
        <state>Florida</state>
        <zip>33408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Sciences Center &amp; ChildrenÂ´s Hospital</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Immunology</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midlands Pediatrics PC</name>
      <address>
        <city>Papillion</city>
        <state>Nebraska</state>
        <zip>68046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop Allergy and Immunology</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Institute of Allergy &amp; Asthma Clinical Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy and Clinical Immunology Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy, Asthma &amp; Immunology Clinic PA</name>
      <address>
        <city>Irving</city>
        <state>Texas</state>
        <zip>75063</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2011</study_first_posted>
  <results_first_submitted>March 10, 2017</results_first_submitted>
  <results_first_submitted_qc>March 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2017</results_first_posted>
  <disposition_first_submitted>September 8, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>September 15, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 29, 2014</disposition_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIDD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 16 study sites in the US.</recruitment_details>
      <pre_assignment_details>Of 54 subjects screened for the study, 37 started treatment. Of the 17 subjects who discontinued the study before treatment, 10 were screen failures, 5 withdrew consent, and for 2 subjects enrollment ended due to other reasons.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous Treatment With IGI, 10% and rHuPH20</title>
          <description>Subcutaneous treatment with IGI, 10% and rHuPH20 occurred in 2 study epochs. In Epoch 1, PIDD patients that were already on intravenous (IV) or subcutaneous (SC) treatment were treated with IGI, 10% and rHuPH20 subcutaneously, with one 1-week dose and interval and one 2-week dose and interval. Epoch 2 was to consist of approx. 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated IV, this treatment was to occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subjectÂ´s previous IV dosing schedule. For subjects pretreated SC, treatment was also to occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject. However, treatment with rHuPH20 was stopped as of August 2012 following a discussion with the FDA, and subjects still active in Epoch 2 were switched to a safety follow-up. During the safety-follow up, subjects received IGI, 10% by either the IV or the SC route.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Epoch 1 (Ramp-up)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated in Epoch 1</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Epoch 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated in Epoch 2</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Switch to safety follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Overall Trial (Incl. Safety Follow-up)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated in Epoch 1 (Ramp-up)</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Epoch 1 (Ramp-up)</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Epoch 2</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated in Epoch 2</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Epoch 2</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Switch to Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">1 subject who completed Epoch 2 + 24 subjects who completed the safety follow-up</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject in Epoch 1</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject in Epoch 2</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event in Epoch 2</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal During Safety-Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous Treatment With IGI, 10% and rHuPH20</title>
          <description>This analysis set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2. In Epoch 1, PIDD patients that were already on intravenous (IV) or subcutaneous (SC) treatment were treated with IGI, 10% and rHuPH20 subcutaneously, with one 1-week dose and interval and one 2-week dose and interval. Epoch 2 was to consist of approx. 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated IV, this treatment was to occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subjectÂ´s previous IV dosing schedule. For subjects pretreated SC, treatment was also to occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject. However, treatment with rHuPH20 was stopped as of August 2012 following a discussion with the FDA, and subjects still active in Epoch 2 were switched to a safety follow-up (IGI, 10% by IV or SC route).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" lower_limit="6" upper_limit="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Related Systemic Adverse Events (Excluding Infections)</title>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Related Systemic Adverse Events (Excluding Infections)</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion</title>
        <description>A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.</description>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
          <group group_id="O2">
            <title>Epoch 2 Data Set (n=36)</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion</title>
          <description>A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.</description>
          <units>adverse events</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.140" upper_limit="0.406"/>
                    <measurement group_id="O2" value="0.253" lower_limit="0.141" upper_limit="0.413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.377" lower_limit="0.205" upper_limit="0.626"/>
                    <measurement group_id="O2" value="0.377" lower_limit="0.205" upper_limit="0.626"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 1+2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.324" lower_limit="0.187" upper_limit="0.517"/>
                    <measurement group_id="O2" value="0.326" lower_limit="0.186" upper_limit="0.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2</title>
        <time_frame>6 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoch 2 Data Set (n=36)</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2</title>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3 or 4-week treatment interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3-week treatment interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-week treatment interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks</title>
        <time_frame>6 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Epoch 2 Data Set (n=36)</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks</title>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Related Local Adverse Events (Excluding Infections)</title>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Related Local Adverse Events (Excluding Infections)</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Related Local Adverse Events (Excluding Infections) Per Infusion</title>
        <description>A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.</description>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
          <group group_id="O2">
            <title>Epoch 2 Data Set (n=36)</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Related Local Adverse Events (Excluding Infections) Per Infusion</title>
          <description>A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.</description>
          <units>adverse events</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.882" lower_limit="0.581" upper_limit="1.271"/>
                    <measurement group_id="O2" value="0.880" lower_limit="0.575" upper_limit="1.278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.811" lower_limit="0.541" upper_limit="1.160"/>
                    <measurement group_id="O2" value="0.811" lower_limit="0.541" upper_limit="1.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 1+2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.841" lower_limit="0.587" upper_limit="1.159"/>
                    <measurement group_id="O2" value="0.840" lower_limit="0.582" upper_limit="1.164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Related Adverse Events (Excluding Infections)</title>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Related Adverse Events (Excluding Infections)</title>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of All Adverse Events (Excluding Infections) Per Infusion</title>
        <description>A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.</description>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
          <group group_id="O2">
            <title>Epoch 2 Data Set (n=36)</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of All Adverse Events (Excluding Infections) Per Infusion</title>
          <description>A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.</description>
          <units>adverse events</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.645" lower_limit="1.221" upper_limit="2.157"/>
                    <measurement group_id="O2" value="1.653" lower_limit="1.221" upper_limit="2.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.642" lower_limit="1.164" upper_limit="2.235"/>
                    <measurement group_id="O2" value="1.642" lower_limit="1.164" upper_limit="2.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 1+2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.643" lower_limit="1.235" upper_limit="2.132"/>
                    <measurement group_id="O2" value="1.646" lower_limit="1.232" upper_limit="2.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20</title>
        <time_frame>7 months (per subject)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20</title>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Levels of Immunoglobulin G (IgG)</title>
        <description>IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.</description>
        <time_frame>7 months (per subject)</time_frame>
        <population>At screening, data (ie, IgG trough levels) were available for analysis from 36 participants. At the end of Epoch 2, data were available for analysis from only 33 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoch 2 Data Set</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Levels of Immunoglobulin G (IgG)</title>
          <description>IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.</description>
          <population>At screening, data (ie, IgG trough levels) were available for analysis from 36 participants. At the end of Epoch 2, data were available for analysis from only 33 participants.</population>
          <units>g/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At screening</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53" lower_limit="9.46" upper_limit="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At end of Epoch 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.21" lower_limit="8.28" upper_limit="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusions Per Month in Epoch 1 and Epoch 2</title>
        <description>Non-parametric descriptive statistics (median, range) are provided.</description>
        <time_frame>7 months (per subject)</time_frame>
        <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusions Per Month in Epoch 1 and Epoch 2</title>
          <description>Non-parametric descriptive statistics (median, range) are provided.</description>
          <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
          <units>infusions</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" lower_limit="2.5" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.6" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2</title>
        <description>Non-parametric descriptive statistics (median, range) are provided.</description>
        <time_frame>7 months (per subject)</time_frame>
        <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2</title>
          <description>Non-parametric descriptive statistics (median, range) are provided.</description>
          <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
          <units>infusion sites (needle sticks)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" lower_limit="2.5" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Infusion in Epoch 1 and Epoch 2</title>
        <description>Non-parametric descriptive statistics (median, range) are provided.</description>
        <time_frame>7 months (per subject)</time_frame>
        <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Infusion in Epoch 1 and Epoch 2</title>
          <description>Non-parametric descriptive statistics (median, range) are provided.</description>
          <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.23" lower_limit="0.53" upper_limit="3.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.67" lower_limit="0.80" upper_limit="3.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Infusion Rate in Epoch 1 and Epoch 2</title>
        <description>Non-parametric descriptive statistics (median, range) are provided.</description>
        <time_frame>7 months (per subject)</time_frame>
        <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Safety Analysis Set (n=37)</title>
            <description>The Safety Analysis Set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Infusion Rate in Epoch 1 and Epoch 2</title>
          <description>Non-parametric descriptive statistics (median, range) are provided.</description>
          <population>The number of participants analyzed for Epoch 1 is 37, as 37 participants were treated with study drug in Epoch 1. The number of participants analyzed for Epoch 2 is 36, as 36 participants were treated with study drug in Epoch 2.</population>
          <units>mL/h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Epoch 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.0" lower_limit="60" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epoch 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300.0" lower_limit="10" upper_limit="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Weeks to Reach Final 3 or 4-week Dose Interval</title>
        <description>Non-parametric descriptive statistics (median, range) are provided.</description>
        <time_frame>7 months (per subject)</time_frame>
        <population>Of 36 participants treated with study drug in Epoch 2, 6 reached a final dose interval of 3 weeks and 30 reached a final dose interval of 4 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Epoch 2 Data Set (n=36)</title>
            <description>The Epoch 2 Data Set comprises all subjects of the safety analysis set who received study drug in Epoch 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Weeks to Reach Final 3 or 4-week Dose Interval</title>
          <description>Non-parametric descriptive statistics (median, range) are provided.</description>
          <population>Of 36 participants treated with study drug in Epoch 2, 6 reached a final dose interval of 3 weeks and 30 reached a final dose interval of 4 weeks.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>3-week dose interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4-week dose interval</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="3" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall: Approximately 1 year Per subject: 7 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Epochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37)</title>
          <description>This analysis set comprises all subjects exposed to study drug in Epoch 1 and Epoch 2. In Epoch 1, PIDD patients that were already on intravenous (IV) or subcutaneous (SC) treatment were treated with IGI, 10% and rHuPH20 subcutaneously, with one 1-week dose and interval and one 2-week dose and interval. Epoch 2 was to consist of approx. 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated IV, this treatment was to occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subjectÂ´s previous IV dosing schedule. For subjects pretreated SC, treatment was also to occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject. However, treatment with rHuPH20 was stopped as of August 2012 following a discussion with the FDA, and subjects still active in Epoch 2 were switched to a safety follow-up (IGI, 10% by IV or SC route).</description>
        </group>
        <group group_id="E2">
          <title>Safety Follow-up (n=26)</title>
          <description>Treatment with rHuPH20 was stopped as of August 2012 following discussion with the FDA. This decision was based on theoretical risks of exposure to anti-rHuPH20 antibodies, not because of any clinical adverse events. 26 subjects still active in Epoch 2 of the study went into a safety follow-up period and were treated with IGI, 10% (GAMMAGARD LIQUID) either intravenously or subcutaneously.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>This event occurred during the safety follow-up period. It was resolved by the time of study completion.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="37"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion site discoloration</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion site erythema</sub_title>
                <counts group_id="E1" events="26" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion site hematoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion site pain</sub_title>
                <counts group_id="E1" events="64" subjects_affected="21" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Infusion site swelling</sub_title>
                <counts group_id="E1" events="23" subjects_affected="9" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemosiderinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vulvovaginal swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxalta's agreements with PIs may vary per requirements of individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or 12 months after study completion. Baxalta requires a review of results communications (e.g., for confidential information) â¥90 days prior to submission or communication. Baxalta may request an additional delay of â¤60 days eg, for intellectual property protection.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Treatment with rHuPH20 was stopped as of August 2012 following discussion with the FDA. 26 subjects still active in Study Epoch 2 went into a safety follow-up period and were treated with IGI, 10% (GAMMAGARD LIQUID) intravenously or subcutaneously.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Registries and Results Disclosure</name_or_title>
      <organization>Baxalta US Inc.</organization>
      <email>ClinicalTrialsDisclosure@baxalta.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

